Voranigo 40 mg Oral Tablet
RxNorm 2690663
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2690663 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Voranigo 40 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
PSNPrescribable
Prescribable Name (PSN):
Voranigo 40 mg Oral Tablet
(Atom ID: 12908072)
SYPrescribable
Synonym (SY):
Voranigo 40 mg Oral Tablet
(Atom ID: 12908071)
SBDPrescribable
Semantic Branded Drug (SBD):
Vorasidenib 40 mg Oral Tablet [Voranigo]
(Atom ID: 12908070)
Patient Education
Vorasidenib
Vorasidenib is used to treat adult and pediatric patients 12 years and older with certain types of astrocytoma or oligodendroglioma that have not improved with surgery. Vorasidenib is in a class of medications called isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitors. It works by blocking enzymes that cause the tumor to grow.
[Learn More]
* Please review the disclaimer below.